Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

DNA polymerase theta inhibitor MOMA-313

An orally bioavailable inhibitor of DNA polymerase (pol) theta helicase, with potential antineoplastic activity. Upon oral administration, DNA polymerase theta inhibitor MOMA-313 specifically targets, binds to and inhibits the pol theta helicase domain and thereby inhibits the activity of pol theta. This prevents pol theta-mediated repair of DNA double-strand breaks (DSBs) via the theta-mediated end joining (TMEJ) process. This causes apoptosis and inhibits proliferation in homologous recombination (HR)-deficient cancer cells. MOMA-313 may have a synergistic effect if administered in combination with a poly (adenosine diphosphate ribose) polymerase (PARP) inhibitor. Pol theta, a DNA helicase-polymerase protein, plays a key role in repair of DNA DSBs through TMEJ and is highly expressed in cancer cells while nearly absent in most healthy tissues. It plays a key role in cancer cell survival. In HR-deficient cancers, DNA DSB repair is impaired and is dependent on pol theta for repair and survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:pol theta inhibitor MOMA-313
polymerase theta helicase inhibitor MOMA-313
Code name:MOMA 313
MOMA-313
MOMA313
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search